International medical imaging IT and cybersecurity company Sectra has agreed to acquire Oxipit, a Lithuanian developer of artificial intelligence solutions for radiology, in a move aimed at expanding autonomous AI capabilities in diagnostic imaging.
Oxipit is known for developing AI systems designed to autonomously perform specific diagnostic tasks in medical imaging. Unlike most AI tools used in radiology today, which primarily support clinicians by highlighting potential findings or prioritizing cases, Oxipit’s technology is built to independently complete certain diagnostic workflows under defined clinical conditions.
One of Oxipit’s flagship products is ChestLink, an AI solution for chest X-ray analysis that can automatically identify and clear high-confidence normal examinations from radiologists’ worklists. By removing routine cases that show no signs of disease, the system allows radiologists to focus more attention on patients with a higher likelihood of pathology. The approach aims to help healthcare providers address growing imaging volumes and ongoing workforce shortages while maintaining strict safety thresholds.
ChestLink has obtained CE Class IIb certification, reflecting a higher regulatory classification under European medical device regulations and enabling its commercialization within the European Economic Area. The solution is already accessible through Sectra’s Amplifier Marketplace for AI, allowing healthcare providers to integrate it into existing radiology workflows.
Founded in 2017, Oxipit has built a portfolio of CE-marked AI products covering chest X-ray, CT, and musculoskeletal imaging applications. Its technologies are currently deployed across multiple international markets.
Following the acquisition, Oxipit will operate as a dedicated AI development center within Sectra’s Imaging IT Solutions business area. Sectra indicated that its Amplifier platform will remain an open and vendor-neutral ecosystem, enabling healthcare providers to access AI applications from a wide range of partners.
The transaction will be financed using Sectra’s own funds and includes an upfront cash payment along with a contingent component tied to future commercial and regulatory milestones. Financial terms of the agreement were not disclosed, and Sectra stated the acquisition is not expected to have a material impact on the group’s sales or operating profit for the current fiscal year.
KEY QUOTE:
“The ability to autonomously clear high-confidence normal cases mark a transformative step for radiology. By combining clinical confidence with intelligent automation, we can expand capacity, reduce radiologist workload, and generate substantial financial benefits through higher productivity and lower cost. We look forward to continuing to sell Oxipit products in Europe and advancing the necessary regulatory approvals to bring it to more markets worldwide.”
Torbjörn Kronander, President And CEO, Sectra
